Witryna13 lut 2024 · In patients with ES-SCLC, in a similar manner to IMPower 133, three RCTs evaluating the efficacy of adding ICI monotherapy in the upfront setting are currently ongoing (nivolumab in ECOG-ACRIN ... Witryna1 paź 2024 · IMpower133 (NCT02763579), a global phase I/III, double-blind, randomized, placebo-controlled trial, showed that adding atezo (anti–PD-L1) to 1L carboplatin + etoposide for ES-SCLC led to a statistically and clinically significant improvement in OS and progression-free survival (PFS) vs carboplatin + etoposide alone.
Tecentriq European Medicines Agency
Witryna1 paź 2024 · IMpower133 (NCT02763579), a global phase I/III, double-blind, randomized, placebo-controlled trial, showed that adding atezo (anti–PD-L1) to 1L carboplatin + … Witryna5 gru 2024 · IMpower 133 trial first confirmed the efficacy and safety of adding atezolizumab or placebo to first-line treatment with chemotherapy in patients with extensive-stage small-cell lung cancer (SCLC). While, overprice limited its broad use in clinical. ... PD1/PD-L1 inhibitors may result in progress in patients with extensive … chimney sweep huntly
Adjuvant atezolizumab after adjuvant chemotherapy in ... - The Lancet
Witryna20 maj 2024 · The IMpower133 Trial in Extensive-Stage SCLC May 20, 2024 Mark A. Socinski, MD Kristie L. Kahl Dr Mark Socinski reviews the IMpower133 trial of first-line … Witryna25 cze 2024 · IMpower133 is a phase III, multicentre, double-blinded, randomised placebo-controlled study evaluating the efficacy and safety of atezolizumab in … WitrynaLearn more about efficacy outcomes in the IMpower 133 clinical trial of TECENTRIQ® (atezolizumab) for extensive-stage small cell lung cancer (ES-SCLC). See full safety for additional information. ... (277/2421) of patients with NSCLC and SCLC receiving TECENTRIQ in combination with platinum-based chemotherapy, including Grade 4 … grady 275 freedom